The North American Thrombosis Forum (NATF) launched an educational initiative on risk assessment and anticoagulation for stroke prevention in atrial fibrillation (AF).
The initiative is sponsored in part by Janssen Pharmaceuticals, which markets oral anticoagulant Xarelto, and by Boehringer Ingelheim, which sells warfarin replacement med Pradaxa.
The goal of the three-year project, according to a statement, is to convene a consensus group of expert researchers and clinicians in the US, Canada, and Europe to synthesize recent clinical trial data and guideline recommendations into one comprehensive and concise “briefing document” for education and reference for the entire medical community involved in the care of patients with AF. The mission is also to provide recommendations regarding anticoagulation options and management.
“There has been an explosion of recent data,” said the leader of the effort Christian Ruff, MD, MPH, an associate physician in the cardiovascular division at Brigham and Women’s Hospital. However, he added, “there’s a real disconnect between the exciting clinical trial data and real-world practical advice for local healthcare providers and nurses and patients.”
A micro-site hosts resources created as part of the ongoing project, including video interviews with leading clinical experts and risk stratification tools.
From the November 01, 2013 Issue of MM+M - Medical Marketing and Media
